Bevacizumab for the early clinical progression of diffuse intrinsic pontine glioma

Pediatr Int. 2023 Jan-Dec;65(1):e15575. doi: 10.1111/ped.15575.

Authors

Mamoru Honda¹, Kohei Fukuoka¹, Yutaka Tanami², Jun Kurihara³, Katsuyoshi Koh¹

Affiliations

¹ Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
² Department of Radiology, Saitama Children's Medical Center, Saitama, Japan.
³ Department of Neurosurgery, Saitama Children's Medical Center, Saitama, Japan.

PMID: 37551654
DOI: 10.1111/ped.15575

No abstract available

Keywords: Bevacizumab; diffuse intrinsic pontine glioma; pseudoprogression.

MeSH terms

Bevacizumab / therapeutic use
Brain Stem Neoplasms* / diagnosis
Brain Stem Neoplasms* / drug therapy
Diffuse Intrinsic Pontine Glioma*
Disease Progression
Humans

Substances

Bevacizumab